Harigai, Masayoshi http://orcid.org/0000-0002-6418-2603
Honda, Suguru http://orcid.org/0000-0003-4846-3234
Funding for this research was provided by:
Japanese Ministry of Health, Labour, and Welfare (H30-menneki-shitei-002)
Article History
First Online: 17 July 2020
Compliance with Ethical Standards
:
: This work was supported by a research grant from the Ministry of Health, Labour, and Welfare (H30-menneki-shitei-002).
: MH has received research grants from AbbVie Japan GK, Asahi Kasei Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Daiichi-Sankyo, Inc., Eisai Co., Ltd., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Nippon Kayaku Co., Ltd., Sekiui Medical, Shionogi & Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd; has received speaker’s fees from AbbVie Japan GK, Ayumi Pharmaceutical Co., Boehringer-Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Kissei Pharmaceutical Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd; and is a consultant for AbbVie, Boehringer-Ingelheim, Bristol Myers Squibb Co., Kissei Pharmaceutical Co., Ltd., and Teijin Pharma. SH has nothing to declare.
: Not applicable.
: Not applicable.
: Not applicable.